Arbekacin inhalation

Drug Profile

Arbekacin inhalation

Alternative Names: ME-1100

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Pharma
  • Class Aminoglycosides; Antibacterials; Cyclohexanols; Cyclohexylamines; Hexosamines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Nosocomial pneumonia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Nosocomial-pneumonia in USA (Inhalation, Liquid)
  • 22 Apr 2017 Antimicrobial activity data from preclinical studies in Nosocomial pneumonia presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 22 Mar 2017 Meiji Seika Pharma completes a phase I trial in Nosocomial pneumonia in USA (NCT02459158)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top